Cargando…
Mycobacterial virulence: impact on immunogenicity and vaccine research
The borderline between virulence and efficacy in live attenuated vaccine strains is often blurred and this is also the case for the Bacillus Calmette–Guérin (BCG), the only currently licensed anti-tuberculosis vaccine used on a large, global scale, which was obtained almost 100 years ago. While BCG...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979476/ https://www.ncbi.nlm.nih.gov/pubmed/32047597 http://dx.doi.org/10.12688/f1000research.20572.1 |
_version_ | 1783490905156616192 |
---|---|
author | Kroesen, Vera M. Madacki, Jan Frigui, Wafa Sayes, Fadel Brosch, Roland |
author_facet | Kroesen, Vera M. Madacki, Jan Frigui, Wafa Sayes, Fadel Brosch, Roland |
author_sort | Kroesen, Vera M. |
collection | PubMed |
description | The borderline between virulence and efficacy in live attenuated vaccine strains is often blurred and this is also the case for the Bacillus Calmette–Guérin (BCG), the only currently licensed anti-tuberculosis vaccine used on a large, global scale, which was obtained almost 100 years ago. While BCG is more than 99% identical at the genome level to Mycobacterium tuberculosis, the causative pathogen of human tuberculosis, some important differences in virulence factors cause naturally irreversible attenuation and safety of this vaccine in the immunocompetent host. Some of these virulence factors are involved in persistence capacities of the vaccine strains and also represent strong immunogens, responsible for inducing different host signaling pathways, which have to be taken into consideration for the development of revised and new vaccine strains. Here we discuss a number of selected mycobacterial features in relation to their biological functions and potential impact on virulence and vaccine efficacy. |
format | Online Article Text |
id | pubmed-6979476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-69794762020-02-10 Mycobacterial virulence: impact on immunogenicity and vaccine research Kroesen, Vera M. Madacki, Jan Frigui, Wafa Sayes, Fadel Brosch, Roland F1000Res Review The borderline between virulence and efficacy in live attenuated vaccine strains is often blurred and this is also the case for the Bacillus Calmette–Guérin (BCG), the only currently licensed anti-tuberculosis vaccine used on a large, global scale, which was obtained almost 100 years ago. While BCG is more than 99% identical at the genome level to Mycobacterium tuberculosis, the causative pathogen of human tuberculosis, some important differences in virulence factors cause naturally irreversible attenuation and safety of this vaccine in the immunocompetent host. Some of these virulence factors are involved in persistence capacities of the vaccine strains and also represent strong immunogens, responsible for inducing different host signaling pathways, which have to be taken into consideration for the development of revised and new vaccine strains. Here we discuss a number of selected mycobacterial features in relation to their biological functions and potential impact on virulence and vaccine efficacy. F1000 Research Limited 2019-11-28 /pmc/articles/PMC6979476/ /pubmed/32047597 http://dx.doi.org/10.12688/f1000research.20572.1 Text en Copyright: © 2019 Kroesen VM et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kroesen, Vera M. Madacki, Jan Frigui, Wafa Sayes, Fadel Brosch, Roland Mycobacterial virulence: impact on immunogenicity and vaccine research |
title | Mycobacterial virulence: impact on immunogenicity and vaccine research |
title_full | Mycobacterial virulence: impact on immunogenicity and vaccine research |
title_fullStr | Mycobacterial virulence: impact on immunogenicity and vaccine research |
title_full_unstemmed | Mycobacterial virulence: impact on immunogenicity and vaccine research |
title_short | Mycobacterial virulence: impact on immunogenicity and vaccine research |
title_sort | mycobacterial virulence: impact on immunogenicity and vaccine research |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979476/ https://www.ncbi.nlm.nih.gov/pubmed/32047597 http://dx.doi.org/10.12688/f1000research.20572.1 |
work_keys_str_mv | AT kroesenveram mycobacterialvirulenceimpactonimmunogenicityandvaccineresearch AT madackijan mycobacterialvirulenceimpactonimmunogenicityandvaccineresearch AT friguiwafa mycobacterialvirulenceimpactonimmunogenicityandvaccineresearch AT sayesfadel mycobacterialvirulenceimpactonimmunogenicityandvaccineresearch AT broschroland mycobacterialvirulenceimpactonimmunogenicityandvaccineresearch |